George Perry
Distinguished as one of the top Alzheimer’s disease researchers with over 1000 publications, one of the top 100 most-cited scientists in neuroscience and behavior. Perry has been cited over 124,000 times (H=175) and is recognized as an ISI highly cited researcher. Perry is editor for numerous journals and is Editor-in-Chief for the Journal of Alzheimer's Disease. He is a fellow of the American Association for the Advancement of Sciences, Sigma Xi (FSX), Microscopy Society of America, World Academy of Medical Sciences (FWAMS), Texas Academy of Sciences, Royal Society of Chemistry (FRSC, CChem), Royal Society of Medicine, Royal College of Pathologists (FRCPath), Royal Society for the encouragement of Arts, Manufacturers and Commerce (FRSA), Royal Society of Biology (FRSB, CBio, CSciTeach, CSci)and the Linnean Society of London (FLS), Royal Microscopical Society (FRMS), EU Academy of Sciences, Past-President of the American Association of Neuropathologists, Past-President and Past-Interim-Executive Director Southwestern and Rocky Mountain Division of the American Association for the Advancement of Science, Foreign Correspondent Member of the Spanish Royal Academy of Sciences, Foreign Corresponding Member of the Academy of Sciences of Lisbon, Corresponding member of the Mexican Academy of Sciences, Doctorado Honoris Causa (Hon. D.)-Universidad Arturo Prat, Iquique, Chile, and member of the Iberoamerican Molecular Biology Organization. He won the Distinguished Professional Mentor award from the Society for the Advancement of Chicanos and Native Americans in Sciences, Senior Investigator Award-International College of Geriatric Psychoneuropharmacology, Martin Goland Award- Alamo Chapter Sigma Xi, Albert Nelson Marquis Lifetime Achievement Award-Marquis Who's Who, UDAAN-Lifetime Achievement Award, Denham Harman Award-American Aging Association, Zenith Award-Alzheimer Association, Mensch Award-Alzheimer Research Forum, Expertscape-Top Specialist in Alzheimer Disease, Notaveis dos Azores, Scientist of the Year-Portuguese Tribune, Senior Fulbright Fellow and the Panama National Plaque of Honor for Excellence in Neuroscience, Distinguished Texas Scientist, Rous-Whipple Award.
Perry's research is primarily focused on how Alzheimer disease develops and the physiological consequences of the disease at a cellular level. He is currently working to determine the sequence of events leading to damage caused by and the source of metabolic abnormalities.
Supervisors: B. R. Brinkley, David Epel, and Pierluigi Gambetti
Phone: +1 210 458 8806
Address: Department of Neuroscience, Developmental and Regenerative Biology
One UTSA Circle
University of Texas at San Antonio
San Antonio, Texas 78249
Perry's research is primarily focused on how Alzheimer disease develops and the physiological consequences of the disease at a cellular level. He is currently working to determine the sequence of events leading to damage caused by and the source of metabolic abnormalities.
Supervisors: B. R. Brinkley, David Epel, and Pierluigi Gambetti
Phone: +1 210 458 8806
Address: Department of Neuroscience, Developmental and Regenerative Biology
One UTSA Circle
University of Texas at San Antonio
San Antonio, Texas 78249
less
InterestsView All (32)
Uploads
deliver as promised, and uncertainty of future finances have drawn industry away
from innovation to reformulation and repackaging. In this new world, academic
research plays an even greater role in drug development, whether built on natural
products or novel insights. Blurring of the lines between the traditional fields of
chemistry and biology offers opportunities for new discoveries. In this milieu
“Recent Advances in Medicinal Chemistry” will find a welcome home.
Table of Contents: Introduction / Plaques / Neurofibrillary Degeneration / Complexities / Synopsis and Conclusion / References / Author Biographies
Using scientometric analysis the most promising developments since the Alzheimer Centennial in 2006 have been substantiated. While prior trends and advances in genetics, amyloid-β, tau, neuropathology, and oxidative stress continue as active areas, emergent areas impacting the transition from normal cognition to Alzheimer’s disease such as diagnostic imaging, biomarkers, metabolism, and lifestyle (areas conceived only a few years ago) now dominate the debate.
Invited contributors have summarized their landmark publications identified by our analysis and have put them into perspective, explaining the impetus behind the work, the contribution of the results to the field, and who played a role in the work."
deliver as promised, and uncertainty of future finances have drawn industry away
from innovation to reformulation and repackaging. In this new world, academic
research plays an even greater role in drug development, whether built on natural
products or novel insights. Blurring of the lines between the traditional fields of
chemistry and biology offers opportunities for new discoveries. In this milieu
“Recent Advances in Medicinal Chemistry” will find a welcome home.
Table of Contents: Introduction / Plaques / Neurofibrillary Degeneration / Complexities / Synopsis and Conclusion / References / Author Biographies
Using scientometric analysis the most promising developments since the Alzheimer Centennial in 2006 have been substantiated. While prior trends and advances in genetics, amyloid-β, tau, neuropathology, and oxidative stress continue as active areas, emergent areas impacting the transition from normal cognition to Alzheimer’s disease such as diagnostic imaging, biomarkers, metabolism, and lifestyle (areas conceived only a few years ago) now dominate the debate.
Invited contributors have summarized their landmark publications identified by our analysis and have put them into perspective, explaining the impetus behind the work, the contribution of the results to the field, and who played a role in the work."